𝔖 Bobbio Scriptorium

✦ LIBER ✦

Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results

✍ Scribed by Fernando M. Stengel; Valeria Petri; Gladys A.M. Campbell; Gladys Leon Dorantes; Magdalina López; Ricardo L. Galimberti; Raúl P. Valdez; Lucia F. De Arruda; Mario Amaya Guerra; Edgardo N. Chouela; Daiana Licu; International IMP25161 Study Group

Book ID: 114911361
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 124 KB
Volume: 2
Category: Article
ISSN: 1753-5174
DOI: 10.1111/j.1753-5174.2009.00024.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of efalizumab for the treatment

Efficacy of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Safety of efalizumab for the treatment o

Safety of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Efficacy and safety of efalizumab in adu

Efficacy and safety of efalizumab in adults with moderate to severe plaque psoriasis and hand and foot involvement: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Safety and tolerability of efalizumab th

Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: Results of an open-label phase IIIb multicenter trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Efficacy and safety of efalizumab in pat

Efficacy and safety of efalizumab in patients with chronic moderate to severe plaque psoriasis: Results from a postapproval phase IIIb/IV study (control II)

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Efficacy and Safety of Efalizumab in Pat

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

✍ Torello Lotti; Sergio Chimenti; Andreas Katsambas; Jean-Paul Ortonne; Louis Dube 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB